Abstract: The present invention provides methods of identifying agents that affect the cleavage of amyloid-&bgr; precursor protein (APP) and related vectors, cells and kits, as well as agents identified by the method.
Type:
Application
Filed:
March 30, 2001
Publication date:
January 30, 2003
Applicant:
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.
Type:
Grant
Filed:
September 26, 1997
Date of Patent:
December 14, 1999
Assignees:
SmithKline Beecham Corporation, University of Texas Southwestern Medical Center at Dallas
Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
November 17, 2009
Assignees:
SmithKline Beecham Corporation, University of Texas Southwestern Medical Center at Dallas